Τρίτη 1 Αυγούστου 2017

Targeting Nectin-4 in Bladder Cancer [News in Brief]

Preliminary findings from a phase I clinical trial indicate that enfortumab vedotin, an investigational antibody–drug conjugate targeting nectin-4, shows considerable efficacy in metastatic urothelial carcinoma. Robust responses were seen even among patients with disease progression on platinum chemotherapy and/or immune checkpoint blockade.



http://ift.tt/2w1YSBm

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου